Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer

This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive nonsmall-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. Patients had pro...

Descripción completa

Detalles Bibliográficos
Autores: Bernabé, Reyes|||0000-0003-0312-9195, Garrido, Pilar|||0000-0002-5899-6125, García-Campelo, Rosario, Palmero, Ramón|||0000-0002-0189-6692, Artal, Ángel, Bayona, Cristina, Rodríguez-Abreu, Delvys|||0000-0003-0506-1366, López-Brea, Marta, Paredes, Alfredo, Vicente, David, Sánchez Torres, José Miguel, Majem Tarruella, Margarita|||0000-0002-9919-7485, Diz Taín, Pilar|||0000-0003-4284-3965, Gordo, Rocío, Coca, Margarita, De Castro, Javier|||0000-0002-3622-6306
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:275219
Acceso en línea:https://ddd.uab.cat/record/275219
https://dx.doi.org/urn:doi:10.18632/oncotarget.28244
Access Level:acceso abierto
Palabra clave:ALK-positive NSCLC
ALK inhibitor
Crizotinib
Alectinib
Unselected patient
Descripción
Sumario:This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive nonsmall-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. Patients had progressed after 1-5 prior treatment lines (which included crizotinib in any prior line) and received subsequent therapy with alectinib in a local expanded access program. Median age was 58.7 years, 50% of patients were female, 64.1% had ECOG PS of 0-1, 85% presented stage IV, 95% had adenocarcinoma histology and 20.8% had brain metastases. After a median 9.6 months of alectinib treatment, objective response rate (ORR) was 54.5%, disease control rate (DCR) was 80%, median progression-free survival (PFS) was 9.4 months and median overall survival (OS) was 24.1 months. Patients with brain metastases achieved an intracranial DCR of 71.4%. Adverse events (AEs) were reported in 35.8% of patients (14.2% of AEs were grade ≥3). Over 40% of patients received some treatment after alectinib, most frequently lorlatinib (65.2%) and brigatinib (32.6%). This study provides information on real-world treatment patterns and confirms the tolerability and prolonged PFS and OS observed with alectinib in clinical trials, in unselected pretreated patients with advanced ALK+ NSCLC.

Similares en LA Referencia